Kringle Pharma, Inc.
http://www.kringle-pharma.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kringle Pharma, Inc.
Deal Watch: Focus Placed On Psoriasis With Recent Purdue, Sienna Deals
Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.
Asia Beat: Japan's bioventure sector needs decisive action
Japan has been attempting to get its bioventure sector off the ground for as long as many in the industry can remember, certainly since I first started coming to the country more than 20 years ago. But progress continues to be glacially slow.
Scrip Asia 100 - Asia's shining stars
The Scrip Asia 100 analysis identifies 100 of the most influential players on the Asia-Pacific life sciences scene. Our shining stars are 10 of Asia's visionary leaders from the worlds of pharma business and science.
Europe venture to take on Kringle's lead project
Kringle Pharma has set up its first overseas operation, a European subsidiary which will progress the clinical development of its lead recombinant hepatic growth factor therapy.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Kringle Pharma Europe AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice